Transfusion of HIV-infected blood products despite highly sensitive nucleic acid testing

Transfusion

Volumn 59, Issue 6, 2019, Pages 2046-2053

  Cappy, Pierre ^a   Barlet, Valérie ^b   Lucas, Quentin ^a   Tinard, Xavier ^b   Pillonel, Josiane ^c   Gross, Sylvie ^b   Tiberghien, Pierre ^b,d   Laperche, Syria ^a  

^a INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

^b ETABLISSEMENT FRANÇAIS DU SANG   (France)

^c SANTÉ PUBLIQUE FRANCE   (France)

^d UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BLOOD DONOR; BLOOD SAFETY; BLOOD TRANSFUSION; CLINICAL ARTICLE; DONOR SELECTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MALE; MIDDLE AGED; NUCLEIC ACID ANALYSIS; NUCLEIC ACID TESTING; RISK ASSESSMENT; VIRUS LOAD; VIRUS TRANSMISSION; BLOOD; CASE REPORT; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; NUCLEIC ACID AMPLIFICATION; SENSITIVITY AND SPECIFICITY; SEROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; VIRUS DNA;

BLOOD DONORS; BLOOD TRANSFUSION; DNA, VIRAL; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; NUCLEIC ACID AMPLIFICATION TECHNIQUES; SENSITIVITY AND SPECIFICITY; SEROLOGIC TESTS; VIRAL LOAD;

EID: 85061837798     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.15203     Document Type: Article

References (47)

1. Busch MP, Stramer SL. Closing the windows on viral transmission by blood transfusion. In: Stramer SL, editor. Blood safety in the new millennium. Bethesda, Md, USA: American Association of Blood Banks (AABB); 2001. P. 1.
2. Roth WK, Busch MP, Schuller A, et al. International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009. Vox Sang 2012;102:82-90.
3. Assal A, Barlet V, Deschaseaux M, et al. Sensitivity of two hepatitis B virus, hepatitis C virus (HCV), and human immunodeficiency virus (HIV) nucleic acid test systems relative to hepatitis B surface antigen, anti-HCV, anti-HIV, and p24/anti-HIV combination assays in seroconversion panels. Transfusion 2009;49:301-10.
4. Seed CR, Kiely P, Keller AJ. Residual risk of transfusion transmitted human immunodeficiency virus, hepatitis B virus, hepatitis C virus and human T lymphotrophic virus. Intern Med J 2005;35:592-8.
5. Zou S, Stramer SL, Dodd RY. Donor testing and risk: current prevalence, incidence, and residual risk of transfusion-transmissible agents in US allogeneic donations. Transfus Med Rev 2012;26:119-28.
6. O'Brien SF, Zou S, Laperche S, et al. Surveillance of transfusion-transmissible infections comparison of systems in five developed countries. Transfus Med Rev 2012;26:38-57.
7. an der Heiden M, Ritter S, Hamouda O, et al. Estimating the residual risk for HIV, HCV and HBV in different types of platelet concentrates in Germany. Vox Sang 2015;108:123-30.
8. Schmidt M, Korn K, Nübling CM, et al. First transmission of human immunodeficiency virus Type 1 by a cellular blood product after mandatory nucleic acid screening in Germany. Transfusion 2009;49:1836-44.
9. Foglieni B, Candotti D, Guarnori I, et al. A cluster of human immunodeficiency virus Type 1 recombinant form escaping detection by commercial genomic amplification assays. Transfusion 2011;51:719-30.
10. Chudy M, Weber-Schehl M, Pichl L, et al. Blood screening nucleic acid amplification tests for human immunodeficiency virus Type 1 may require two different amplification targets. Transfusion 2012;52:431-9.
11. Müller B, Nübling CM, Kress J, et al. How safe is safe: new human immunodeficiency virus type 1 variants missed by nucleic acid testing. Transfusion 2013;53(10 Pt 2):2422-30.
12. Rambaut A, Posada D, Crandall KA, et al. The causes and consequences of HIV evolution. Nat Rev Genet 2004;5:52-61.
13. Mansky LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 1995;69:5087-94.
14. Curlin ME, Gottlieb GS, Hawes SE, et al. No evidence for recombination between HIV type 1 and HIV type 2 within the envelope region in dually seropositive individuals from Senegal. AIDS Res Hum Retroviruses 2004;20:958-63.
15. Mourez T, Simon F, Plantier J-C. Non-M variants of human immunodeficiency virus type 1. Clin Microbiol Rev 2013;26:448-61.
16. Jetzt AE, Yu H, Klarmann GJ, et al. High rate of recombination throughout the human immunodeficiency virus type 1 genome. J Virol 2000;74:1234-40.
17. Zhuang J, Jetzt AE, Sun G, et al. Human immunodeficiency virus type 1 recombination: rate, fidelity, and putative hot spots. J Virol 2002;76:11273-82.
18. Hemelaar J. The origin and diversity of the HIV-1 pandemic. Trends Mol Med 2012;18:182-92.
19. LANL HIV sequence databases [Internet]. [accessed 2018 Dec 20] Available from: https://www.hiv.lanl.gov/.
20. Henquell C, Jacomet C, Antoniotti O, et al. Difficulties in diagnosing group O human immunodeficiency virus type 1 acute primary infection. J Clin Microbiol 2008;46:2453-6.
21. Plantier JC, Djemai M, Lemee V, et al. Census and analysis of persistent false-negative results in serological diagnosis of human immunodeficiency virus type 1 group O infections. J Clin Microbiol 2009;47:2906-11.
22. Avidor B, Matus N, Girshengorn S, et al. Comparison between Roche and Xpert in HIV-1 RNA quantitation: a high concordance between the two techniques except for a CRF02_AG subtype variant with high viral load titters detected by Roche but undetected by Xpert. J Clin Virol 2017;93:15-9.
23. van der Loeff MFS, Awasana AA, Sarge-Njie R, et al. Sixteen years of HIV surveillance in a West African research clinic reveals divergent epidemic trends of HIV-1 and HIV-2. Int J Epidemiol 2006;35:1322-8.
24. Eholié S, Anglaret X. Commentary: decline of HIV-2 prevalence in West Africa: good news or bad news? Int J Epidemiol. Oxford University Press 2006;35:1329-30.
25. Truant AL. Manual of commercial methods. In: Truant AL, Tang Y-W, Waites KB et al., editors. Clinical Microbiology. Hoboken, NJ: John Wiley & Sons; 2016. p. 1.
26. Stramer SL, Chambers L, Page PL, et al. Third reported US case of breakthrough HIV transmission from NAT screened blood. Transfusion 2003;43:40A-41A.
27. Delwart EL, Kalmin ND, Jones TS, et al. First report of human immunodeficiency virus transmission via an RNA-screened blood donation. Vox Sang 2004;86:171-7.
28. Najioullah F, Barlet V, Renaudier P, et al. Failure and success of HIV tests for the prevention of HIV-1 transmission by blood and tissue donations. J Med Virol 2004;73:347-9.
29. Phelps R, Robbins K, Liberti T, et al. Window-period human immunodeficiency virus transmission to two recipients by an adolescent blood donor. Transfusion 2004;44:929-33.
30. Harritshoj LH, Dickmeiss E, Hansen MB, et al. Transfusion-transmitted human immunodeficiency virus infection by a Danish blood donor with a very low viral load in the preseroconversion window phase. Transfusion 2008;48:2026-8.
31. Kalus U, Edelmann A, Pruss A, et al. Noninfectious transfusion of platelets donated before detection of human immunodeficiency virus RNA in plasma. Transfusion 2009;49:435-9.
32. Laffoon B, Levi M, Bower WA, Kuehnert M, Brooks JT, Selik RM, et al. HIV transmission through transfusion. MMWR Morb Mortal Wkly Rep 2010;1–4.
33. Salles NA, Levi JE, Barreto CC, et al. Human immunodeficiency virus transfusion transmission despite nucleic acid testing. Transfusion 2013;53(10 Pt 2):2593-5.
34. Sobata R, Shinohara N, Matsumoto C, et al. First report of human immunodeficiency virus transmission via a blood donation that tested negative by 20-minipool nucleic acid amplification in Japan. Transfusion 2014;54:2361-2.
35. Rujirojindakul P. First report of Human Immunodeficiency Virus breakthrough transmission in Thailand after mandatory 6-minipool nucleic acid testing. Vox Sang 2015;109(Suppl.1):1-379.
36. Álvarez M, Luis-Hidalgo M, Bracho MA, et al. Transmission of human immunodeficiency virus Type-1 by fresh-frozen plasma treated with methylene blue and light. Transfusion 2016;56:831-6.
37. Laperche S, Tiberghien P, Roche-Longin C, et al. Fifteen years of nucleic acid testing in France: results and lessons. Transfus Clin Biol 2017;24:182-8.
38. Assal A, Barlet V, Deschaseaux M, et al. Comparison of the analytical and operational performance of two viral nucleic acid test blood screening systems: Procleix Tigris and Cobas S 201. Transfusion 2009;49:289-300.
39. Barin F, Meyer L, Lancar R, et al. Development and validation of an immunoassay for identification of recent human immunodeficiency virus type 1 infections and its use on dried serum spots. J Clin Microbiol 2005;43:4441-7.
40. De Oliveira F, Mourez T, Vessière A, et al. Multiple HIV-1/M + HIV-1/O dual infections and new HIV-1/MO inter-group recombinant forms detected in Cameroon. Retrovirology 2017;14:1.
41. Kumar S, Stecher G, Tamura K. MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets. Mol Biol Evol 2016;33:1870-4.
42. Vermeulen M, Lelie N, Coleman C, et al. Assessment of HIV transfusion transmission risk in South Africa: a 10-year analysis following implementation of individual donation nucleic acid amplification technology testing and donor demographics eligibility changes. Transfusion 2018;17(Suppl 1):854.
43. Kleinman S, van Drimmelen H, Lelie N, et al. Minipool NAT HIV-1 breakthrough transmission cases and probability of interdiction by current small pool or individual-dination NAT screening systems. Vox Sang 2018;96(Suppl 1):1-62.
44. Le Vu S, Le Strat Y, Barin F, et al. Population-based HIV-1 incidence in France, 2003-08: a modelling analysis. Lancet Infect Dis 2010;10:682-7.
45. Ma Z-M, Stone M, Piatak M, et al. High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection. JVirol 2009;83:3288-97.
46. Kleinman SH, Lelie N, Busch MP. Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion. Transfusion 2009;49:2454-89.
47. de Souza MS, Pinyakorn S, Akapirat S, et al. Initiation of antiretroviral therapy during acute HIV-1 infection leads to a high rate of nonreactive HIV serology. Clin Infect Dis 2016;63:555-61.